ISIN
SE0008015259
Ticker
IBT
Sector
Sub-Industry
Country
Sweden
Year Founded
2013
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants.
IBT is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
08.02.2024 | Anthon Jahreskog | Other | Buy | SEK 79,033.80 |
08.02.2024 | Anthon Jahreskog | Other | Buy | SEK 15,134.00 |
09.06.2023 | Maria Ekdahl | Other | Buy | SEK 49,956.00 |
23.05.2023 | Anders Kronström | Other | Buy | SEK 56,482.50 |
23.05.2023 | Anthon Jahreskog | Other | Buy | SEK 36,593.00 |
23.05.2023 | Maria Ekdahl | Other | Buy | SEK 19,995.00 |
23.05.2023 | Anthon Jahreskog | Other | Buy | SEK 6,377.20 |
23.05.2023 | Anthon Jahreskog | Other | Buy | SEK 6,269.92 |
22.05.2023 | Maria Ekdahl | Other | Buy | SEK 30,487.00 |
20.05.2023 | Anders Kronström | Other | Buy | SEK 82,250.00 |
SE0008015259
2138008KVBXCRJGP6Z26
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.